Related Experiment Video
Updated: Oct 29, 2025
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
IL13 Fused Pseudomonas Exotoxin Targets Various Cancers In Vitro
Damla Uludağ1,2, Nihal Karakaş3,4
1Medical Biology and Genetics Program, Graduate School for Health Sciences, Istanbul Medipol University, Istanbul, Turkey.
Background/Aim:
Pseudomonas exotoxin (PE) is one of the most widely used toxins in the construction of therapeutic fusion proteins in pre-clinical studies followed by phase trials. In principle, PE acts by blocking protein synthesis through catalyzing the inactivation of elongation factor-2 (EF-2). The interleukin-13 fused PE (IL13-PE) cytotoxin was previously designed to target GBM cells. In this study, the cytotoxic effects of IL13-PE were evaluated in 5 different types of cancers and the therapeutic effects were further analyzed in a lung cancer cell line, NCI-H460. Conceptually, in another lung cancer cell line (A549), IL13Rα2 was overexpressed by lentiviruses (A549-IL13Rα2) and evaluated for cytotoxic efficacy of IL13-PE.
Materials And Methods:
The expression profile of IL13Rα2 in different cancer cell lines was determined by RT-PCR. Secretable toxin fusion was expressed in the toxin resistant HEK-293T cell line (293T-TxR) by using a plasmid coding for IL13-PE and IRES-GFP (LV-IL13-PE-IRES/GFP). Next, the cells were shown to produce and secrete functional IL13-PE by dot blot analysis, followed by cell viability assays and cell death analysis.
Results:
Upon treatment with IL13-PE, a significant decrease in cell viability was selectively demonstrated in cancer cells with cognate receptor expression. IL13-PE treatment increased the apoptotic/necrotic cell populations in the NCI-H460 cell line.
Conclusion:
Our results demonstrate that IL13-PE can be a therapeutic target for tumors bearing mostly IL13Rα2 positive cell populations. Our findings also suggest a cell-based delivery option for the recombinant toxins in the treatment of different cancers which can provide a solution for the clinical use of toxin therapy.
Insights
Interleukin-13 fused Pseudomonas exotoxin (IL13-PE) effectively reduced cancer cell viability in tumors expressing the IL13Rα2 receptor. This study highlights IL13-PE as a promising therapeutic agent and suggests cell-based delivery for toxin therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Pseudomonas exotoxin (PE) is a widely used toxin for therapeutic fusion proteins.
- IL13-PE was designed to target glioblastoma multiforme (GBM) cells.
- PE functions by inhibiting protein synthesis via elongation factor-2 (EF-2) inactivation.
Purpose of the Study:
- To evaluate the cytotoxic effects of IL13-PE in five cancer types.
- To analyze the therapeutic efficacy of IL13-PE in a lung cancer cell line (NCI-H460).
- To assess IL13-PE's efficacy in an engineered A549 lung cancer cell line overexpressing IL13Rα2.
Main Methods:
- RT-PCR was used to determine IL13Rα2 expression in cancer cell lines.
- Secretable IL13-PE was expressed in HEK-293T cells using a lentiviral vector.
- Functional IL13-PE secretion was confirmed by dot blot, followed by cell viability and death assays.
Main Results:
- IL13-PE treatment selectively decreased cell viability in cancer cells expressing the IL13Rα2 receptor.
- Apoptotic and necrotic cell populations increased in the NCI-H460 lung cancer cell line upon IL13-PE treatment.
Conclusions:
- IL13-PE is a potential therapeutic agent for tumors with high IL13Rα2 expression.
- Cell-based delivery of recombinant toxins offers a viable strategy for cancer toxin therapy.
More Related Videos
09:01Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
Published on: July 3, 2025
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
